OmniAb's Innovation Paradox: Groundbreaking Tech vs. Financial Woes

EMERYVILLE, CA – March 04, 2026 – OmniAb, Inc. finds itself at a critical juncture, navigating a paradox that has become increasingly common in the biotech sector: groundbreaking scientific innovation clashing with challenging financial realities. The company’s full-year 2025 earnings report, released this week, painted a picture of a business expanding its technological prowess and partner base while simultaneously grappling with declining revenues and a widening net loss, leaving investors and analysts to weigh near-term struggles against long-term promise.

While the antibody discovery firm celebrated the launch of its novel OmniUltra™ platform and the progress of its partners' clinical pipelines, the underlying financial metrics told a more sobering story. The company's stock, despite optimistic "Strong Buy" ratings from several analysts, has reflected the broader market caution toward cash-burning biotech firms, underscoring the high-stakes environment in which it operates.

A Tale of Two Reports

On the surface, OmniAb's operational highlights for 2025 suggest a company on the rise. CEO Matt Foehr pointed to an expanded base of 107 active partners and a growing portfolio of 407 active programs. "Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure," Foehr stated in the press release.

However, the financial statements present a starkly different narrative. For the full year 2025, OmniAb reported total revenue of $18.7 million, a significant 29% drop from $26.4 million in 2024. This decline was primarily attributed to decreases in license and service revenue. The fourth quarter showed a similar trend, with revenue falling to $8.4 million from $10.8 million in the same period a year prior.

The bottom line worsened in tandem with falling revenue. The company posted a net loss of $64.8 million for 2025, an increase from the $62.0 million loss recorded in 2024. The cash position, a crucial metric for pre-profitability biotech companies, also continued its downward trend. OmniAb ended 2025 with $54.0 million in cash, cash equivalents, and short-term investments, down from $59.4 million at the end of 2024 and $87.0 million at the end of 2023.

Looking ahead, the company's 2026 guidance projects revenues between $25 million and $30 million, a potential rebound, but also anticipates cash costs and operating expenses in the range of $50 million to $55 million. This forecast suggests the cash burn will continue, with the company expecting to end 2026 with cash reserves between $30 million and $35 million, further tightening its financial runway.

A Bet on 'Biological Intelligence'

Despite the financial headwinds, OmniAb is making an aggressive bet that its technological innovation will be its ultimate salvation. The centerpiece of this strategy is the recently launched OmniUltra™ platform. Unveiled in December 2025, OmniUltra is a transgenic chicken engineered to produce antibodies with ultralong CDRH3 domains—a feature designed to target unique and previously inaccessible parts of disease-causing proteins.

More revolutionary, the platform can generate picobodies™, which OmniAb describes as the smallest known natural antibody-derived binding domains. At just 4–6 kilodaltons, picobodies are roughly one-third the size of a nanobody, a class of small antibodies that has already opened new therapeutic frontiers. This miniaturization could enable the development of highly targeted therapies, including bispecifics, CAR-T cells, and radioligands, that can penetrate tissues more effectively and address targets beyond the reach of conventional antibodies.

This move into novel antibody formats is complemented by the xPloration® partner access program. Launched in May 2025, this program allows partners to purchase and use OmniAb's proprietary high-throughput single B-cell screening instrument in their own labs. By leveraging machine learning, the platform can screen millions of cells and identify thousands of unique antibody candidates in mere hours, dramatically accelerating the discovery process. This not only provides a new revenue stream but also more deeply embeds OmniAb's technology within its partners' R&D ecosystems.

The Pipeline is the Lifeline

Ultimately, OmniAb’s long-term value proposition hinges on the success of its partners. The company’s business model relies on a mix of upfront fees, service revenue, and, most importantly, future milestone payments and royalties from approved drugs. With 407 active programs underway, including 32 OmniAb-derived assets in clinical development or on the market, the company has built a large and diverse portfolio of shots on goal.

Several of these partnered programs are approaching critical inflection points. Immunovant's IMVT-1402 is advancing in multiple potentially registrational trials for autoimmune diseases, with key data readouts expected in 2026 and 2027. Teva Pharmaceuticals is also expecting topline results this year for its anti-IL-15 antibody TEV-'408 in vitiligo and celiac disease.

Perhaps most notably, Merck KGaA plans to advance its antibody-drug conjugate precemtabart tocentecan into a Phase 3 trial for metastatic colorectal cancer in 2026, based on promising Phase 1 data. A successful Phase 3 trial and subsequent commercialization of a drug for a major cancer indication would trigger substantial milestone and royalty payments, fundamentally altering OmniAb's financial trajectory. As Foehr noted, the company sees "several later-stage assets... emerging with potential to generate meaningful milestones and, ultimately, recurring royalty revenue."

Navigating a Cautious Market

For now, OmniAb remains a company of dualities. Wall Street analysts see immense potential, with many maintaining "Strong Buy" ratings and price targets that suggest a possible upside of over 200% from its current trading price. They point to the company's powerful technology, expanding pipeline, and a management team that is prudently managing costs.

However, investors are balancing that long-term optimism against the harsh realities of the current market, which has been unforgiving to biotech companies without significant revenue or near-term profitability. The path forward for OmniAb is clear but challenging: it must leverage its innovative platforms like OmniUltra to secure new, high-value partnerships while carefully managing its cash. Its future is inextricably linked to the clinical and commercial success of its partners, making every upcoming data release and regulatory filing a pivotal event. The company has built a powerful engine for drug discovery; the question that remains is whether it can get to the destination of sustainable profitability before it runs out of fuel.